Company intelligence / Profile preview
Suzhou Shengji Pharmaceutical
Suzhou, Jiangsu Sheng, Chinatracxn.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
The company is developing a biosimilar of choriogonadotropin alfa targeting female infertility, currently in Phase 1. Developing a novel erythropoiesis stimulant targeting chronic renal failure anemia in clinical stages. Pipeline includes recombinant human follicle-stimulating hormone-CTP fusion protein for female infertility in Phase 3 clinical stage.
- Therapeutic areas
- NephrologyWomen's Health
- Modalities
- BiosimilarHormoneColony-stimulating factors
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Suzhou Kangju BIOTECHNOLOGY Co., Ltd.
Beyond the preview
Go deeper on Suzhou Shengji Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Shengji Pharmaceutical.